Discovery of Novel PD-L1 Inhibitors That Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.3c01534 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Kaizhen Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, B7-H1 Antigen. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Postdoctoral Research Foundation of China, Jiangsu Planned Projects for Postdoctoral Research Funds, Ministry of Science and Technology of the People's Republic of China.
Abstract (Originalsprache)
Tumor cells can evade immune surveillance through overexpressing programmed cell death-ligand 1 (PD-L1) to interact with programmed cell death-1 (PD-1). Besides, tumor-intrinsic PD-L1 is involved in tumor progression without interaction with PD-1, which provides more challenges for the discovery of PD-L1 inhibitors. Herein, we report the discovery of novel PD-L1 inhibitors using the fragment coupling strategy. Among them, B9 was found to inhibit the PD-1/PD-L1 interaction with the best IC50 value of 1.8 ± 0.7 nM. Beyond the blockade of the PD-1/PD-L1 axis, B9 promotes the dimerization, internalization, and degradation of PD-L1. Furthermore, B9 displayed high in vivo antitumor efficacy in the CT26 mouse model and activated the immune microenvironment and induced PD-L1 degradation of PD-L1 in the tumor. These results show that B9 is a promising lead PD-L1 inhibitor through the blockade of PD-1/PD-L1 interaction and functional inhibition of the PD-L1 signal pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
ORCID-Profile: Xiangyu Zhang, Kuojun Zhang, Sheng Jiang, Yi Liu, Tianyu Wang
Förderung
- Postdoctoral Research Foundation of China
- Jiangsu Planned Projects for Postdoctoral Research Funds
- Ministry of Science and Technology of the People's Republic of China
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Wang, K., Zhang, X., Cheng, Y., Qi, Z., Ye, K., Zhang, K., Jiang, S., Liu, Y., Xiao, Y., & Wang, T. (2023). Discovery of Novel PD-L1 Inhibitors That Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01534
Vancouver
Wang K, Zhang X, Cheng Y, Qi Z, Ye K, Zhang K, et al. Discovery of Novel PD-L1 Inhibitors That Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c01534
BibTeX
@article{Wang2023,
author = {Wang, Kaizhen and Zhang, Xiangyu and Cheng, Yao and Qi, Zhihao and Ye, Ke and Zhang, Kuojun and Jiang, Sheng and Liu, Yi and Xiao, Yibei and Wang, Tianyu},
title = {Discovery of Novel PD-L1 Inhibitors That Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.3c01534}
}
EUVIMED